Tillman Gerngross is taking a group of antibodies identified by his discovery group Adimab and handing them over to Arsanis, a Vienna-based biotech he co-founded to develop some of the programs he has set up at the mother ship in Lebanon, NH. And the biotech has a $9.3 million grant from the Bill & Melinda Gates Foundation to get the work through IND-enabling studies.
The target this time is RSV, or respiratory syncytial virus, which infects the respiratory system.
Gerngross has done a number of these kinds of deals, parlaying the advances at Adimab over the years into new programs at the biotechs he’s aligned with. He took the chairman’s role at Arsanis, which is based in Vienna, around the lab of CSO Eszter Nagy, an Intercell veteran.
Their lead drug — ASN-100 — is a mAb in Phase II development for the prevention of serious cases of pneumonia.
“Arsanis’ partnerships with Adimab and the Gates Foundation will allow us to apply our deep expertise in the discovery and development of anti-infective antibodies to advance highly potent human monoclonal antibodies for the prevention of RSV infection,” said Rene Russo, Arsanis’ chief executive, in prepared text. “We believe this approach has the potential to address a significant global need for effective and accessible RSV therapeutics in both developed and developing countries.”
The best place to read Endpoints News? In your inbox.
Full-text daily reports for those who discover, develop, and market drugs. Join 21,000+ biopharma pros who read Endpoints News by email every day.Free Subscription